RBCC to develop sustained-release drug delivery platform
The firm claims that the new delivery system can help in a better way to deliver biologic agents and small molecules in a safer, more effective and more
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
Under the agreement, Jazz will develop Concert’s deuterium-modified sodium oxybate (D-SXB) compounds, including C-10323, and will have worldwide commercial rights to C-10323 as well as principal responsibility for
Non-systemic chewable complex carbohydrate-based drug is a proprietary polysaccharide which blocks the action of carbohydrate-hydrolyzing enzymes that break down carbohydrates into glucose and release it into the bloodstream.
Under the deal, Althea will supply gram-scale quantities of current Good Manufacturing Practice (cGMP) manufactured plasmid DNA expressing IL-12 to assist Profectus Biosciences’ ongoing DNA vaccine development program.